CD38 Controls Tumor Immune Suppression Across Multiple Cell Types
A comprehensive review reveals CD38 as a master metabolic and immunologic regulator sustaining tumor immune evasion—and a promising therapy target.
Summary
CD38 is a multifunctional enzyme expressed on multiple immune-suppressive cell types in the tumor microenvironment (TME), including Tregs, MDSCs, Bregs, TAMs, and TANs. By hydrolyzing NAD+, generating calcium-mobilizing messengers, and promoting fatty acid oxidation, CD38 sustains the survival and suppressive activity of these regulatory cells while impairing effector T cell function. This review from Mayo Clinic scientists frames CD38 as a 'master regulator of regulators' and highlights therapeutic strategies—monoclonal antibodies like daratumumab, small-molecule inhibitors, and checkpoint inhibitor combinations—that could dismantle these interconnected suppressive networks to restore antitumor immunity.
Detailed Summary
The immunosuppressive tumor microenvironment (TME) remains a central obstacle in cancer immunotherapy. While checkpoint inhibitors and adoptive cell therapies have transformed oncology, many patients fail to respond, largely because suppressive immune circuits within the TME remain intact. This comprehensive review, authored by researchers at Mayo Clinic, positions CD38—a multifunctional ectoenzyme and surface glycoprotein—as a master coordinator of these circuits.
CD38 is highly expressed on the very immune cell populations that drive tumor immune evasion: regulatory T cells (Tregs), regulatory B cells (Bregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs). On these cells, CD38 sustains survival, metabolic fitness, and suppressive capacity through three interlocking mechanisms: (1) NAD+ hydrolysis, which depletes extracellular NAD+ and starves effector T cells of glycolytic and mitochondrial substrates; (2) generation of second messengers cyclic ADP-ribose (cADPR) and NAADP, which mobilize intracellular calcium and activate transcriptional programs (STAT3, NFAT, NF-κB) that reinforce suppressive phenotypes; and (3) promotion of fatty acid oxidation (FAO) in regulatory cells, enabling their metabolic persistence under hypoxic, nutrient-depleted TME conditions.
The review also highlights a noncanonical adenosinergic pathway in which CD38 cooperates with CD203a and CD73 to convert NAD+ ultimately into adenosine—a potent suppressor of T cell and NK cell activity via A2A and A2B receptors. In CD38+ Bregs, hypoxia-induced HIF-1α stabilization drives FAO gene expression (CPT1A, PPARα/γ), supporting angiogenesis and immune evasion. High CD38 expression on CD8+/CD4+ T cells itself correlates with exhaustion markers (PD-1, LAG-3) and poor response to checkpoint blockade. Invariant NKT (iNKT) cells also upregulate CD38 upon activation, suggesting a context-dependent role in shaping pro- or anti-tumor immune fate.
Therapeutically, the review synthesizes evidence for multiple CD38-targeting strategies: FDA-approved monoclonal antibodies daratumumab and isatuximab (well-established in multiple myeloma), bispecific constructs, antibody-drug conjugates, and small-molecule NAD+ synthesis inhibitors such as FK866. Crucially, the authors argue that combining CD38 inhibition with immune checkpoint blockade or TAM-reprogramming agents could simultaneously dismantle multiple suppressive nodes rather than addressing each cell type in isolation. Emerging findings on CD38's intracellular localization in mitochondria and the nucleus—and its role in epigenetic regulation via mitochondrial NAD+ pools—further expand its potential as a therapeutic target beyond surface depletion.
In summary, this review provides an integrated framework establishing CD38 as both a metabolic checkpoint and an immunologic signaling orchestrator. Its expression across diverse suppressive cell populations makes it an unusually attractive target for 'regulating the regulators'—dismantling the shared metabolic and signaling infrastructure of TME immunosuppression to restore effective antitumor immunity.
Key Findings
- CD38 sustains Tregs, MDSCs, Bregs, TAMs, and TANs through NAD+ depletion, calcium signaling, and fatty acid oxidation.
- CD38 generates adenosine via a noncanonical pathway, suppressing effector T cell and NK cell activity in the TME.
- In CD38+ Bregs, HIF-1α-driven FAO gene induction promotes angiogenesis and therapeutic resistance under hypoxia.
- High CD38 on CD8+/CD4+ T cells correlates with exhaustion markers PD-1 and LAG-3 and poor checkpoint blockade response.
- Combining CD38-targeted antibodies or inhibitors with checkpoint blockade shows promise for dismantling multi-node immunosuppression.
Methodology
This is a comprehensive narrative review synthesizing published literature on CD38 biology, immune cell metabolism, and cancer immunology. The authors integrate mechanistic, preclinical, and clinical evidence to construct a conceptual framework positioning CD38 as a master regulator of TME immunosuppression. No original experimental data were generated.
Study Limitations
As a review, this work does not provide new experimental data, and causal claims about CD38's role in specific TME contexts rely on heterogeneous preclinical and correlative clinical evidence. The therapeutic strategies discussed are largely exploratory for solid tumors, with most clinical validation limited to hematologic malignancies. The complexity of CD38's context-dependent roles—particularly in iNKT cells—means that broad targeting strategies could have unpredictable immunologic consequences.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.